• Mashup Score: 1

    Daniel Spratt engages with Amar Kishan about the role of transcriptomic profiling and PSMA PET imaging in prostate cancer. Dr. Kishan discusses a study involving 18 trials and 12,500 patients, which suggests that extra-prostatic disease is often the driver of distant metastasis in high-risk patients. The study also explores the correlation between Decipher scores and the risk of upstaging on…

    Tweet Tweets with this article
    • #Decipher scores and PSMA PET imaging: A correlative study in high-risk #ProstateCancer. @AmarUKishan @UCLA joins @DrSpratticus @caseccc to discuss the role of transcriptomic profiling and PSMA PET imaging in prostate cancer > https://t.co/bt51iKY23O @Decipher_VCYT @Veracyte https://t.co/3Cjo6HVi1b

  • Mashup Score: 6

    Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights…

    Tweet Tweets with this article
    • Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT https://t.co/RVn1XxJzGL

  • Mashup Score: 0

    Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights…

    Tweet Tweets with this article
    • Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT https://t.co/YKMKrlqbuj

  • Mashup Score: 2

    Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic…

    Tweet Tweets with this article
    • The rationale for the use of #Decipher RP genomic classifier to inform treatment. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/RyTjNIj0aI @Decipher_VCYT @Veracyte https://t.co/j6njX23P8G

  • Mashup Score: 5

    Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights…

    Tweet Tweets with this article
    • Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT https://t.co/Lp8rbK4hty

  • Mashup Score: 0

    Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic…

    Tweet Tweets with this article
    • The rationale for the use of #Decipher RP genomic classifier to inform treatment. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/RyTjNIj0aI @Decipher_VCYT @Veracyte https://t.co/akLMcY4bjq

  • Mashup Score: 1

    Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights…

    Tweet Tweets with this article
    • Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT https://t.co/6Djn19jjSC

  • Mashup Score: 1

    Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic…

    Tweet Tweets with this article
    • The rationale for the use of #Decipher RP genomic classifier to inform treatment. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/RyTjNIj0aI @Decipher_VCYT @Veracyte https://t.co/Kd1lFAleYX